NCT01458977View on ClinicalTrials.gov

Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions

HIVDyslipidemia

Interventions

DRUG

Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)

TDF/FTC 300/200mg daily during 3 months + Placebo during 6 months

DRUG

Placebo

Placebo during 3 months + TDF/FTC 300/200mg daily during 3 months + Placebo during 3 months

Trial Locations (3)

08916

Germans Trias i Pujol Hospital, Badalona

08035

Hospital Valle Hebrón, Barcelona

Unknown

Hospital de Bellvitge, L'Hospitalet de Llobregat

All Listed Sponsors

lead

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

NCT01458977 - Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors | Biotech Hunter | Biotech Hunter